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Human cancer cells typically harbour multiple chromosomal aberrations, nucleotide substitutions and epigenetic 
modifications that drive malignant transformation. The Cancer Genome Atlas (TCGA) pilot project aims to assess the value 
of large-scale multi-dimensional analysis of these molecular characteristics in human cancer and to provide the data rapidly 
to the research community. Here we report the interim integrative analysis of DNA copy number, gene expression and DNA 
methylation aberrations in 206 glioblastomas-the most common type of primary adult brain cancer-and nucleotide 
sequence aberrations in 91 of the 206 glioblastomas. This analysis provides new insights into the roles of ERBB2, NF1 and 
TP53, uncovers frequent mutations of the phosphatidylinositol-3-0H kinase regulatory subunit gene PIK3R1, and provides a 
network view of the pathways altered in the development of glioblastoma. Furthermore, integration of mutation, DNA 
methylation and clinical treatment data reveals a link between MGMT promoter methylation and a hypermutator phenotype 
consequent to mismatch repair deficiency in treated glioblastomas, an observation with potential clinical implications. 
Together, these findings establish the feasibility and power of TCGA, demonstrating that it can rapidly expand knowledge of 
the molecular basis of cancer. 
Cancer is a disease of genome alterations: DNA sequence changes, 
copy number aberrations, chromosomal rearrangements and modi­
fication in DNA methylation together drive the development and 
progression of human malignancies. With the complete sequencing 
of the human genome and continuing improvement of high­
throughput genomic technologies, it is now feasible to contemplate 
comprehensive surveys of human cancer genomes. The Cancer 
Genome Atlas aims to catalogue and discover major cancer-causing 
genome alterations in large cohorts of human tumours through inte­
grated multi-dimensional analyses. 
The first cancer studied by TCGA is glioblastoma (World Health 
Organization grade IV), the most common primary brain tumour in 
adults'. Primary glioblastoma, which comprises more than 90% of 
biopsied or resected cases, arises de nova without antecedent history 
of low-grade disease, whereas secondary glioblastoma progresses 
from previously diagnosed low-grade gliomas 1 • Patients with newly 
diagnosed glioblastoma have a median survival of approximately 
1 year with generally poor responses to all therapeutic modalities2 • 
Two decades of molecular studies have identified important genetic 
events in human glioblastomas, including the following: (1) dysre­
gulation of growth factor signalling via amplification and mutational 
activation of receptor tyrosine kinase (RTK) genes; (2) activation of 
the phosphatidylinositol-3-OH kinase (PI(3)K) pathway; and (3) 
inactivation of the p53 and retinoblastoma tumour suppressor path­
ways1. Recent genome-wide profiling studies have also shown 
remarkable genomic heterogeneity among glioblastoma and the 
existence of molecular subclasses within glioblastoma that may, when 
fully defined, allow stratification of treatment3-8• Albeit fragmentary, 
such baseline knowledge of glioblastoma genetics sets the stage to 
explore whether novel insights can be gained from a more systematic 
examination of the glioblastoma genome. 
*Lists of participants and their affiliations appear at the end of the paper. 
Results 
Data release. As a public resource, all TCGA data are deposited at 
the Data Coordinating Center (DCC) for public access (http:// 
cancergenome.nih.gov/). TCGA data are classified by data type (for 
example, clinical, mutations, gene expression) and data level to allow 
structured access to this resource with appropriate patient privacy 
protection. An overview of the data organization is provided in the 
Supplementary Methods, and a detailed description is available in the 
TCGA Data Primer (http://tcga-data.nci.nih.gov/docs/TCGA_Data_Frimer. 
pelf). 
Biospecimen collection 
Retrospective biospecimen repositories were screened for newly 
diagnosed glioblastoma based on surgical pathology reports and clin­
ical records (Supplementary Fig. 1). Samples were further selected for 
having matched normal tissues as well as associated demographic, 
clinical and pathological data (Supplementary Table 1). 
Corresponding frozen tissues were reviewed at the Biospecimen 
Core Resource (BCR) to ensure a minimum of 80% tumour nuclei 
and a maximum of 50% necrosis (Supplementary Fig. 1). DNA and 
RNA extracted from qualified biospecimens were subjected to addi­
tional quality control measurements (Supplementary Methods) 
before distribution to TCGA centres for analyses (Supplementary 
Fig. 2). 
After exclusion based on insufficient tumour content (n = 234) 
and suboptimal nucleic acid quality or quantity (n = 147), 206 of the 
587 biospecimens screened (35%) were qualified for copy number, 
expression and DNA methylation analyses. Of these, 143 cases had 
matched normal peripheral blood or normal tissue DNAs and were 
therefore appropriate for re-sequencing. This cohort also included 21 
post-treatment glioblastoma cases used for exploratory comparisons 
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(Supplementary Table I). Although it is possible that a small number 
of progressive secondary glioblastomas were among the remaining 
185 cases of newly diagnosed glioblastomas, this cohort represents 
predominantly primary glioblastoma. Indeed, when compared with 
published cohorts, overall survival of the newly diagnosed glioblas­
toma cases in TCGA is similar to that of primary glioblastomas 
reported in the literature (Supplementary Fig. 3, P = 0.2)9-12•
Genomic and transcriptional aberrations 
Genomic copy number alterations (CNAs) were measured on three 
microarray platforms (Supplementary Methods) and analysed with 
multiple analytical algorithms13-15 (Supplementary Fig. 4 and
Supplementary Tables 2-4). In addition to the well-known altera­
tions3 ·13 ·1•, we detected significantly recurrent focal alterations not
previously reported in glioblastomas, such as homozygous deletions 
involving NFI and PARK2, and amplifications of AKT3 (Fig. la and 
Supplementary Tables 2-4). Search for informative but infrequent 
CNAs also uncovered rare focal events, such as amplifications of 
FGFR2 and IRS2, and deletion of PTPRD (Supplementary Table 4). 
Abundance of protein-coding genes and non-coding microRNA was 
also measured by transcript-specific and exon-specific probes on 
multiple platforms (Supplementary Methods). The resulting inte­
grated gene expression data set showed that �76% of genes within 
recurrent CNAs have expression patterns that correlate with copy 
number (Supplementary Table 2). In addition, single-nucleotide­
polymorphism (SNP)-based analyses also catalogued copy-neutral 
loss ofheterozygosity (LOH), with the most significant region being 
17p, which contains TP53 (Supplementary Methods). 
Patterns of somatic nucleotide alterations in glioblastoma 
A total of 91 matched tumour-normal pairs (72 untreated and 19 
treated cases) were selected from the 143 cases for detection of 
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somatic mutations in 601 selected genes (Supplementary Table 5). 
The resulting sequences, totalling 97 million base pairs (I.I± 0.1 
million bases per sample), uncovered 453 validated non-silent so­
matic mutations in 223 unique genes, 79 of which contained two or 
more events (Supplementary Table 6; see also http://tcga-data.nci.­
nih.gov/docs/somatic_mutations/tcga_mutations.htm). The back­
ground mutation rates differed markedly between untreated and 
treated glioblastomas, averaging 1.4 versus 5.8 somatic silent muta­
tions per sample (98 events among 72 untreated cases versus 111 
among 19 treated, P < 10-21 ), respectively. This difference was pre­
dominantly driven by seven hypermutated samples, as determined by 
frequencies ofboth silent and non-silent mutations (Fig. lb, c). Four 
of the seven hypermutated tumours were from patients previously 
treated with temozolomide and three were from patients treated with 
CCNU (lomustine) alone or in combination (Supplementary Table 
lb). A hypermutator phenotype in glioblastoma has been described 
in three glioblastoma specimens with MSH6 mutations16•17, prompt­
ing us to perform a systematic analysis of the genes involved in 
mismatch repair (MMR). Indeed, six of the seven hypermutated 
samples harboured mutations in at least one of the MMR genes 
MLHI, MSH2, MSH6 or PMS2, as compared with only one sample 
among the eighty-four non-hypermutated samples (P = 7 X 10-8), 
suggesting a role of decreased DNA repair competency in these highly 
mutated samples derived from treated patients. 
By applying a statistical analysis of mutation significance18, we
identified eight genes as significantly mutated ( false discovery 
rate< I 0-3) (Fig. 2d and Supplementary Table 6). Interestingly, 27
TP53 mutations were detected in the 72 untreated glioblastomas 
(37.5%) and 11 mutations in the 19 treated samples (58%). All of 
those mutations clustered in the DNA binding domain, a well-known 
hotspot for p53 mutations in human cancers (Supplementary Fig. 5 
and Supplementary Table 6). Given the predominance of primary 
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Figure 1 I Significant copy number aberrations and pattern of somatic 
mutations. a, Frequency and significance of focal high-level CNAs. Known 
and putative target genes are listed for each significant CNA, with 'Number of 
genes' denoting the total number of genes within each focal CNA boundary. 
b, c, Distribution of the number of silent (b) and non-silent (c) mutations 
across the 91 glioblastoma samples separated according to their treatment 
Treated: 5 4 3 4 6 1 2 1 
Untreated: 27 24 12 11 5 9 5 5 
status, showing hypermutation in 7 out of the 19 treated samples. 
d, Significantly mutated genes in 91 glioblastomas. The eight genes attaining a 
false discovery rate <0.l are displayed here. Somatic mutations occurring in 
untreated samples are in dark blue; those found in statistically non­
hypermutated and hypermutated samples among the treated cohort are in 
respectively lighter shades ofblue. Numbers of events in each group are noted. 
glioblastoma among this newly diagnosed collection, that result 
unequivocally proves that p53 mutation is a common event in prim­
ary glioblastoma. 
NFl is a human glioblastoma suppressor gene. Although somatic 
mutations in NFl have been reported in a small series of human 
glioblastoma tumours19
, 
their role remains controversial20
, 
despite 
strong genetic data in mouse model systems20-22• Here, 19 NFJ so­
matic mutations were identified in 13 samples ( 14% of91), including 
6 nonsense mutations, 4 splice site mutations, 5 missense changes 
and 4 frameshift insertions/deletions (indels) (Fig. 2a). Five of these 
mutations-R1391S (ref. 23), R1513* (ref. 24), e25 -1 and e29 +1 
(ref. 25) and Q1966* (ref. 26)-have been reported as germline 
alterations in neurofibromatosis patients, and thus are probably 
inactivating. In addition, 30 heterozygous deletions in NFl were 
observed among the entire interim sample set of206 cases, 6 of which 
also harbour point mutation (Supplementary Tables 8 and 9). Some 
samples also exhibited loss of expression without evidence of geno­
mic alteration (Fig. 2b). Overall, at least 47 of these 206 patient 
samples (23%) harboured somatic NFl inactivating mutations or 
deletions, definitively addressing NFJ's relevance to sporadic human 
glioblastoma. 
Prevalence of EGFR family activation. EGFR is frequently activated 
in primary glioblastomas. Variant Ill deletion of the extracellular 
domain ('vIII mutant')27 has been the most commonly described 
event, in addition to extracellular domain point mutations and cyto­
plasmic domain deletions28•29 • Here, high-resolution genomic and 
exon-specific transcriptomic profiling readily detected vIII and car­
boxy-terminal deletions with correspondingly altered transcripts 
(Fig. 2c). Among the 91 glioblastoma cases with somatic mutation 
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Figure 2 I Mutations in NFJ tumour suppressor gene and EGFR family 
members. a, NFl somatic mutations in 91 glioblastoma tumours. Both 
missense mutations and truncating nonsense, frameshift and splice site 
mutations were observed. Splice positions are given in number of bases to 
the closest exon ( e#) numbered according to the NF 1 reference transcript in 
the Human Gene Mutation Database; positive indicates 3' of exon, negative 
indicates 5' of exon. Asterisk indicates a stop codon. fs, frameshift. 
b, Correlation of copy number and mutation status at the NFl locus with 
level of expression (y axis). Mutation events predicted to result in fewer 
expressed copies (including deletion, nonsense, splice site and frameshift 
mutations) generally have lower observed expression. HomoDel, 
homozygous deletion; HemiDel, single-copy loss; Neutral, no change in 
copy number (presumed diploid); Amp, increased copy number. Copy 
number status of the NFl locus in each sample was determined as described 
in the Supplementary Information. c, DNA copy number and mRNA 
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data, 22 harboured focal amplification of wild-type EGFR with no 
point mutation, 16 had point mutations in addition to focal amp­
lification, and 3 had EGFR point mutations but no amplification 
(Supplementary Fig. 6 and Supplementary Table 9). Collectively, 
EGFR alterations were observed in 41 of the 91 sequenced samples. 
ERBB2 mutation has previously been reported in only one glio­
blastoma tumour30• In the TCGA cohort, 11 somatic ERBB2 muta­
tions in 7 of 91 samples were validated, including 3 in the kinase 
domain and 2 involving V777 A, a site of recurrent missense and 
in-frame insertion mutations in lung, gastric and colon cancers31 • 
The remaining eight mutations (including seven missense and one 
splice-site mutation) occurred in the extracellular domain of the 
protein, similar to somatic EGFR substitutions in glioblastoma 
(Fig. 2d). Unlike in breast cancers, focal amplifications of ERBB2 
were not observed in glioblastomas. 
Somatic mutations of the PI(3)K complex in human glioblastoma. 
The PI(3)K complex consists of a catalytically active protein, pl l0cx, 
encoded by PJK3CA, and a regulatory protein, p85cx, encoded by 
PIK3Rl. Frequent activating missense mutations of PIK3CA have 
been reported in multiple tumour types, including glioblastoma32'33• 
These mutations occur primarily in the adaptor binding domain 
(ABD) as well as the C2 helical and kinase domains34-36• Indeed, 
PJK3CA somatic nucleotide substitutions were detected in 6 of the 
91 sequenced samples (Supplementary Table 6). Apart from the four 
mutations already reported in the COSMIC database (http:// 
www.sanger.ac.uk/genetics/CGP/cosmic/), two novel in-frame dele­
tions were detected in the adaptor binding domain of PIK3CA 
('LI0del' and 'Pl7del'). Those deletions may disrupt interactions 
between pl lOcx and its regulatory subunit, p85cx (ref. 37). 
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Unlike PIK3CA, PIK3Rl has rarely been reported as mutated in 
cancers. Among the five reported PIK3Rl nucleotide substitutions in 
cancers38'39, one was in a glioblastoma39 • In our TCGA cohort, 9 
PIK3Rl somatic mutations were detected among the 91 sequenced 
glioblastomas. None of them was in samples with PIK3CA mutations. 
Of the nine mutations, eight lay within the intervening SH2 ( or iSH2) 
domain and four are 3-bp in-frame deletions (Fig. 3a and 
Supplementary Table 6). In accord with the crystal structure of 
PI(3)K, which identifies the D560 and N564 amino acid residues in 
p85a as contact points with the N345 amino acid residue in the C2 
domain of pll0a (ref. 37), the mutations detected in glioblastoma 
cluster around those three amino acid residues (Fig. 3b), including a 
N345K mutation in PIK3CA (previously reported in colon and breast 
cancers40 ) and D560Y and N564K mutations in PIK3Rl. We also 
identified an 18-bp deletion spanning residues D560 to S565 
(DKRMNS) in PIK3Rl (Fig. 3b) in addition to three other novel 
deletions (R574del, T576del and W583del) in proximity to the two 
key residues. We speculate that spatial constraints due to these dele­
tions might prevent inhibitory contact of the p85:x N-terminal SH2 
(nSH2) domain with the helical domain of pll0a, causing constitu­
tive PI(3)K activity. Taken together, the pattern of clustering of the 
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mutations around key residues defined by the crystal structure of 
PI(3)K strongly suggests that these novel PIK3Rl point mutations 
and indels disrupt the important C2-iSH2 interaction, relieving the 
inhibitory effect of p85!X on p 11 0:x. 
MGMT methylation and MMR in treated glioblastomas 
Cancer-specific DNA methylation of CpG dinucleotides located in 
CpG islands within the promoters of2,305 genes was measured relative 
to normal brain DNA (Supplementary Table 7 and Supplementary 
Methods). The promoter methylation status of MGMT, a DNA repair 
enzyme that removes alkyl groups from guanine residues4 1, is asso­
ciated with glioblastoma sensitivity to alkylating agents42'43• Among the
91 sequenced cases, 19 samples were found to contain MGMT pro­
moter methylation ( including 13 of the 72 untreated cases and 6 of the 
19 treated cases). When juxtaposed with somatic mutation data, an 
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number below each bar indicates the number of samples in the group. Bars 
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intriguing relationship between the hypermutator phenotype and 
MGMT methylation status emerged in the treated samples. 
Specifically, MGMTmethylation was associated with a profound shift 
in the nucleotide substitution spectrum of treated glioblastomas 
(Fig. 4a). Among the 13 treated samples without MGMTmethylation, 
29% (29 out of99) of the validated somatic mutations occurred as G•C 
to A •T transitions in CpG dinucleotides ( characteristic of spontaneous 
deamination of methylated cytosines), and a comparable 23% (23 out 
of99) of all mutations occurred as G•C toA•T transitions in non-CpG 
dinucleotides. In contrast, in the six treated samples with MGMT 
methylation, 81 % of all mutations ( 146 out of 181) turned out to be 
of the G•C to A•T transition type in non-CpG dinucleotides, whereas 
only 4% (8 out of 181) of all mutations were G•C to A•T transition 
mutations within CpGs. That pattern is consistent with a failure to 
repair alkylated guanine residues caused by treatment. In other words, 
MGMTmethylation shifted the mutation spectrum of treated samples 
to a preponderance of G•C to A •T transition at non-CpG sites. 
Notably, the mutational spectra in the MMR genes themselves 
reflected MGMT methylation status and treatment consequences. 
All seven mutations in MMR genes found in six MGMT methylated, 
hypermutated (treated) tumours occurred as G•C to A•T mutations 
at non-CpG sites (Fig. 4b and Supplementary Table 6), whereas 
neither MMR mutation in non-methylated, hypermutated tumours 
was of this characteristic. Hence, these data show that MMR defi­
ciency and MGMTmethylation together, in the context of treatment, 
exert a powerful influence on the overall frequency and pattern of 
somatic point mutations in glioblastoma tumours, an observation of 
potential clinical importance. 
Integrative analyses define glioblastoma core pathways 
To begin to construct an integrated view of common genetic altera­
tions in the glioblastoma genome, we mapped the unequivocal genetic 
a 
 
alterations-validated somatic nucleotide substitutions, homozygous 
deletions and focal amplifications-onto major pathways implicated 
in glioblastoma1 • That analysis identified a highly interconnected net­
work of aberrations (Supplementary Figs 7 and 8), including three 
major pathways: RTK signalling, and the p53 and RB tumour sup­
pressor pathways (Fig. 5). 
By copy number data alone, 66%, 70% and 59% of the 206 samples 
harboured somatic alterations in core components of the RB, TP53 
and RTK pathways, respectively (Supplementary Table 8). In the 91 
samples for which there was also sequencing data, the frequencies of 
somatic alterations increased to 87%, 78% and 88%, respectively 
(Supplementary Table 9). There was a statistical tendency towards 
mutual exclusivity of alterations of components within each pathway 
(P-values of 9.3 X 10-10, 2.5 X 10-13 and 0.022, respectively, for the
p53, RB and RTK pathways; Supplementary Table IO), consistent 
with the thesis that deregulation of one component in the pathway 
relieves the selective pressure for additional ones. However, we 
observed a greater than random chance ( one-tailed, P = 0.0018) that 
a given sample harbours at least one aberrant gene from each of the 
three pathways (Supplementary Table 10). In fact, 74% harboured 
aberrations in all three pathways, a pattern suggesting that deregula­
tion of the three pathways is a core requirement for glioblastoma 
pathogenesis. 
As well as frequent deletions and mutations of the PTEN lipid 
phosphatase tumour suppressor gene, 86% of the glioblastoma sam­
ples harboured at least one genetic event in the core RTK/PI3K path­
way (Fig. Sa). In addition to EGFR and ERBB2, PDGFRA (13%) and 
MET ( 4%) showed frequent aberrations (Supplementary Table 9). A 
total of 10 of the 91 sequenced samples have amplifications or point 
mutations in at least 2 of the 4 RTKs catalogued (EGFR, ERBB2,
PDGFRA and MET; Supplementary Table 9), suggesting that geno­
mic activation can be a mechanism for co-activated RTKs44 • 
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Figure 5 I Frequent genetic alterations in three critical signalling 
pathways. a-c, Primary sequence alterations and significant copy number 
changes for components of the RTK/RAS/PI(3)K (a), p53 (b) and RB 
( c) signalling pathways are shown. Red indicates activating genetic
alterations, with frequently altered genes showing deeper shades of red.
Conversely, blue indicates inactivating alterations, with darker shades 
corresponding to a higher percentage of alteration. For each altered 
component of a particular pathway, the nature of the alteration and the 
percentage of tumours affected are indicated. Boxes contain the final 
percentages of glioblastomas with alterations in at least one known 
component gene of the designated pathway. 
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Inactivation of the p53 pathway occurred in the form of ARF 
deletions (SS%), amplifications of MDM2 (11%) and MDM4 
(4%), in addition to mutations of pS3 itself (Fig. Sb and Supple­
mentary Table 8). Among 91 sequenced samples (Supplementary 
Table 9), genetic lesions in TP53 were mutually exclusive of those 
in MDM2 or MDM4 ( odds ratios of0.00 for both; P = 0.02 and 0.068, 
respectively; Supplementary Table 10), but not of those in ARP. In 
fact, 10 of the 32 tumours with TP53 mutations also had deleted ARP, 
suggesting that homozygous deletion of the CDKN2A locus (which 
encodes both pl61NK4A and ARF) was at least in part driven by
pl6INK4A_
Among the 77% samples harbouring RB pathway aberrations 
(Fig. Sc), the most common event was deletion of the CDKN2A/ 
CDKN2B locus on chromosome 9p21 (SS% and S3%), followed by 
amplification of the CDK4 locus (14%) (Fig. Sc and Supplementary 
Tables 8 and 9). Although CNAs in the CDK/RB pathway members 
can co-occur in the same tumour14, all nine samples with RBI nuc­
leotide substitutions (Supplementary Table 9) lacked CDKN2AI 
CDKN2B deletion or other CNAs in the pathway, suggesting that 
inactivation of RBI by nucleotide substitution, in contrast to copy 
number loss, obviates the genetic pressure for activation of upstream 
cyclin/cyclin-dependent kinases. 
Discussion 
In establishing this pilot programme, TCGA has developed important 
principles in biospecimen banking and collection, and established the 
infrastructure that will serve similar efforts in the future. Although it 
ensured high-quality data, the stringent biospecimen selection criteria 
may have introduced a degree of bias because small samples and 
samples with high levels of necrosis were excluded. Nonetheless, the 
clinical parameters of this cohort are similar to other published 
cohorts (Supplementary Fig. 3 and Supplementary Table 1). 
The integrated analyses of multi-dimensional genomic data from 
complementary technology platforms have proved informative. In 
addition to pinpointing deregulation of RB, pS3 and RTK/RAS/ 
PI(3)K pathways as obligatory events in most, and perhaps all, glio­
blastoma tumours, the patterns of mutations may also inform future 
therapeutic decisions. It would be reasonable to speculate that 
patients with deletions or inactivating mutations in CDKN2A or 
CDKN2C or patients with amplifications of CDK4/CDK6would be 
candidates for treatment with CDK inhibitors, a strategy not likely to 
be effective in patients with RBI mutation. Similarly, patients with 
PTEN deletions or activating mutations in PIK3CA or PIK3R1 might 
be expected to benefit from a PI(3)K or PDKl inhibitor, whereas 
tumours in which the Pl(3)K pathway is altered by AKT3 amplifica­
tion might prove refractory to those modalities. The presence of 
genomic co-amplification reinforces the recent report of multiple 
phosphorylated (activated) RTKs in individual glioblastoma speci­
mens44, suggesting a way to tailor anti-RTK therapeutic cocktails to
specific patterns of RTK mutation. In addition, combination anti­
RTK therapy might synergize with downstream inhibition of PI(3)K 
or cell cycle mediators. In contrast, glioblastomas with NFl muta­
tions might benefit from a RAF or MEK inhibitor as part of a com­
bination, as shown for BRAP mutant cancers45.
One of the most important biomarkers for glioblastomas is the 
methylation status of MGMT, which predicts sensitivity to temozo­
lomide42'43, an alkylating agent that is the current standard of care for
glioblastoma patients. Integrative analysis of mutation, DNA methy­
lation and clinical (treatment) data, albeit with small sample num­
bers, suggests a series of inter-related events that may have an impact 
on clinical response and outcome. Newly diagnosed glioblastomas 
with MGMT methylation respond well to treatment with alkylating 
agents, in part as a consequence of unrepaired alkylated guanine 
residues initiating cycles of futile mismatch repair, which can lead 
to cell death46-<8• Therefore, treatment of MGMT-deficient glioblas­
tomas with alkylating therapy introduces a strong selective pressure 
to lose mismatch repair function49 • That conclusion is consistent with 
 
our observation that the mismatch repair genes themselves are 
mutated with characteristic C•G to A•T transitions at non-CpG sites 
resulting from unrepaired alkylated guanine residues. Thus, initial 
methylation of MGMT, in conjunction with treatment, may lead to 
both a shift in mutation spectrum affecting mutations at mismatch 
repair genes and selective pressure to lose mismatch repair function. 
In other words, our finding raises the possibility that patients who 
initially respond to the frontline therapy in use today may evolve not 
only treatment resistance, but also an MMR-defective hypermutator 
phenotype. If such a hypothesis is validated, one may speculate that 
selective strategies designed to target mismatch-repair-deficient 
cells50 would represent a rational upfront combination with alkylat­
ing agent that together may prevent or minimize emergence of such 
resistance. Conversely, such a treatment-mediated mutator pheno­
type may enhance pathway mutations that can confer resistance to 
targeted therapies, thereby cautioning the combination of alkylating 
agents with targeted agents, as this may substantially increase the 
probability of developing resistance to such targeted drugs. 
The power of TCGA to produce unprecedented multi-dimen­
sional data sets using statistically robust numbers of samples sets 
the stage for a new era in the discovery of new cancer interventions. 
The integrative analyses leading to the formulation of an unantici­
pated hypothesis on a potential mechanism of resistance highlights 
precisely the value and power of such project design, demonstrating 
how unbiased and systematic cancer genome analyses oflarge sample 
cohorts can lead to important discoveries. 
METHODS SUMMARY 
Biospecimens were screened from retrospective banks of tissue source sites under 
appropriate Institutional Review Board approvals for newly diagnosed glioblas­
toma with minimal 80% tumour cell percentage. RNA and DNA extracted from 
qualified specimens were distributed to TCGA centres for analysis. Whole-gen­
ome-amplified genomic DNA samples from tumours and normal samples were 
sequenced by the Sanger method. Mutations were called, verified using a second 
genotyping platform, and systematically analysed to identify significantly 
mutated genes after correcting for the background mutation rate for nucleotide 
type and the sequence coverage of each gene. DNA copy number analyses were 
performed using the Agilent 244K, Affymetrix SNP6.0 and Illumina 550K DNA 
copy number platforms. Sample-specific and recurrent copy number changes 
were identified using various algorithms (GISTIC, GTS, RAE). Messenger RNA 
and microRNA (miRNA) expression profiles were generated using Affymetrix 
Ul33A, AffymetrixExon 1.0 ST, custom Agilent 244K, and Agilent miRNA array 
platforms. mRNA expression profiles were integrated into a single estimate of 
relative gene expression for each gene in each sample. Methylation at CpG 
dinucleotides was measured using the Illumina GoldenGate assay. All data for 
DNA sequence alterations, copy number, mRNA expression, miRNA expression 
and CpG methylation were deposited in standard common formats in the TCGA 
DCC at http://cancergenome.nih.gov/dataporta1/. All archives submitted to 
DCC were validated to ensure a common document structure and to ensure 
proper use of identifying information. 
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